期刊文献+

二线阿西替尼治疗晚期肾癌患者的疗效及不良反应

Efficacy and safety of second-line axitinib in the treatment of advanced renal cell carcinoma
收藏 分享 导出
摘要 目的:评价二线阿西替尼治疗晚期肾癌患者的疗效及安全性。方法:回顾性分析2009年10月~2011年9月于我院泌尿外科诊治的15例接受二线阿西替尼治疗的晚期肾癌患者。所有患者均接受肾根治性切除手术,病理均为透明细胞癌。11例患者一线舒尼替尼治疗后进展,4例患者一线免疫治疗后进展。二线治疗方案:初始剂量5mg、2次/d,连续4周为一周期直至疾病再次进展或不可耐受的严重毒副反应。若患者对药物耐受好,剂量可增至7mg、2次/d,或10mg、2次/d,若毒副反应重则剂量减至3mg、2次/d。结果:Kaplan-Meier生存分析提示这15例患者中位总位生存期(OS)23.0(18.0~28.0)个月。二线阿西替尼治疗的中位无进展生存期(PFS)为7.0(1.5~47.0)个月。根据RECIST标准评价最佳疗效:完全缓解(CR)0例(0),部分缓解(PR)3例(20.0%),疾病稳定(SD)8例(53.3%),疾病进展(PD)4例(26.7%)。多数不良反应多为1~2级,3~4级不良反应有蛋白尿2例(13.3%),腹泻1例(6.7%),呕吐2例(13.3%),乏力消瘦2例(13.3%),高血压5例(33.3%),手足皮肤反应1例(6.7%),口腔黏膜炎1例(6.7%),肝酶升高1例(6.7%),脑梗死1例(6.7%),上消化道出血1例(6.7%)。通过减量或暂停药,多数不良反应可以耐受。结论:二线阿西替尼治疗晚期肾癌可取得较长的OS和PFS,二线治疗有较高疾病控制率,且不良反应多可耐受。 Objective:To investigate the efficacy and safety of axitinib in the treatment of advanced renal cell carcinoma.Method:A retrospective study of 15 patients with advanved renal cell carcinoma treated with secondline axitinib in Peking University First Hospital between Oct.2009 and Sep.2011.All patients underwent radical nephrectomy and the pathological characteristics are all clear cell carcinomas.Eleven cases received sunitinib as first-line therapy,and another 4 cases received first-line immunotherapy.But they all experienced disease progression.Second-line axitinib was administered 5 mg twice daily,four weeks a period repeatedly until disease progression or severe adverse effect occurred.For patients without severe adverse effect 7 mg twice daily or even10 mg twice daily monotherapy can be used.Dose reduction to 3 mg twice daily can also be used if needed.Result:The median overall survival of the 15 patients was 23.0(range,18.0-28.0)months,and the median progression free surival was 7.0(range,1.5-47.0)months.The best efficacy results showed:0 patient(0)achieved complete recession,3 patients(20.0%)experienced partial recession,8 patients(53.3%)showed stable disease,4 patients(26.7%)developed progressive disease.Most adverse effects were graded 1 or 2.Severe adverse effects included 2(13.3%)patients with proteinuria,1(6.7%)patient with diarrhea,2(13.3%)patients with vomiting,2(13.3%)patients with weight decreased and fatigue,5(33.3%)patients with hypertension,1(6.7%)patient with hand-foot syndrome,1(6.7%)patient with mucosal inflammation,1(6.7%)patient with decreased liver function,1(6.7%)patient with cerebral thrombosis,1(6.7%)patient with upper gastrointestinal bleeding.Most adverse effects were ameliorated by dose reduction or temporary drug interruption.Conclusion:The study shows second-line axitinib can achieve promising OS and PFS for Chinese patients with advanced renal cell carcinoma,with satisfactory efficacy and manageable adverse effect events.
作者 余霄腾 唐琦 李学松 彭鼎 宋毅 虞巍 张争 何志嵩 张崔建 周利群 YU Xiaoteng;TANG Qi;LI Xuesong;PENG Ding;SONG Yi;YU Wei;ZHANG Zheng;HE Zhisong;ZHANG Cuijian;ZHOU Liqun(Department of Urology,Peking University First Hospital,Institute of Urology,Peking University,National Urological Cancer Center,Beijing,100034,China)
出处 《临床泌尿外科杂志》 2019年第5期366-370,共5页 Journal of Clinical Urology
关键词 肾癌 肿瘤晚期 靶向治疗 阿西替尼 renal cell carcinoma advanced tumor targeted therapy axitinib
作者简介 通信作者:张崔建,E-mail:surgeon_zhang@126.com
  • 相关文献

参考文献2

二级参考文献33

  • 1Schwaab T,Schwarzer A,Wolf B,et al.Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin(Interleukin 2)and IFN-{alpha}2atherapy in metastatic renal cell carcinoma patients[J].Clin Cancer Res,2009,15(15):4986-4992. 被引量:1
  • 2Su X,Zhang L,Jin L,et al.Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma[J].Cancer Biother Radiopharm,2010,25(4):465-470. 被引量:1
  • 3Atkins M B,Regan M,McDermott D.Update on the role of interleukin 2and other cytokines in the treatment of patients with stage IV renal carcinoma[J].Clin Cancer Res,2004,10(18Pt 2):6342-6346. 被引量:1
  • 4Buti S,Rovere R K,Donini M,et al.Changes in lymphocyte count induced by repeated cycles with low-dose interleukin-2and interferon-alpha in 146patients with renal cell carcinoma[J].Tumori,2012,98(1):45-52. 被引量:1
  • 5Gupta K,Miller J D,Li J Z,et a1.Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma(mRCC):a literature review[J].Cancer Treat Rev,2008,34(3):193-205. 被引量:1
  • 6Motzer R J,Barrios C H,Kim T M,et al.PhaseⅡrandomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and everolimus in patients with metastatic renal cell carcinoma[J].J Clin Oncol,2014,32(25):2765-2772. 被引量:1
  • 7Escudier B,Szczylik C,Hutson T E,et al.Randomized phaseⅡtrial of first-line treatment with sorafenib versus interferon Alfa-2ain patients with metastatic renal cell carcinoma[J].J Clin Oncol,2009,27(8):1280-1289. 被引量:1
  • 8Motzer R J,Nosov D,Eisen T,et al.Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma:results from a phaseⅢtrial[J].J Clin Oncol,2013,31(30):3791-3799. 被引量:1
  • 9Motzer R J,Hutson T E,Tomczak P,et al.Sunitinib versus interferon alfa in metastatic renal cell carcinoma[J].N Engl J Med,2007,356(2):115-124. 被引量:1
  • 10Sternberg C N,Davis I D,Mardiak J,et al.Pazopanib in locally advanced or metastatic renal cell carcinoma:results of a randomized phase III trial[J].J Clin Oncol,2010,28(6):1061-1068. 被引量:1

共引文献6

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈